Switch to:
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Novo Nordisk A/S (NYSE:NVO)
Accounts Payable & Accrued Expense
$3,392 Mil (As of Dec. 2016)

Novo Nordisk A/S's quarterly accounts payable & accrued expense declined from Jun. 2016 ($1,498 Mil) to Sep. 2016 ($1,459 Mil) but then increased from Sep. 2016 ($1,459 Mil) to Dec. 2016 ($3,392 Mil).

Novo Nordisk A/S's annual accounts payable & accrued expense increased from Dec. 2014 ($2,984 Mil) to Dec. 2015 ($3,079 Mil) and increased from Dec. 2015 ($3,079 Mil) to Dec. 2016 ($3,392 Mil).


Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Novo Nordisk A/S Annual Data

Accounts Payable & Accrued Expense 4044285767387897832,8102,9843,0793,392

Novo Nordisk A/S Quarterly Data

Accounts Payable & Accrued Expense 1,0652,9841,0511,0781,0773,0791,2841,4981,4593,392
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)